Trials / Terminated
TerminatedNCT00047827
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
A Phase 2, Open-Label, Non-Comparative Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) as First-Line Therapy in the Treatment of Invasive Aspergillosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Micafungin | IV |
| DRUG | Liposomal Amphotericin B | IV |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2003-02-01
- Completion
- 2003-02-01
- First posted
- 2002-10-24
- Last updated
- 2014-08-20
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00047827. Inclusion in this directory is not an endorsement.